Kilitch Drugs vs Sakar Healthcare vs Shree Ganesh Remedies: Which Stock Should You Track
- October 21, 2026
- Posted by: Neeraj Pandey
- Category: Market
Kilitch Drugs (India) PE 29.19, mkt cap Rs 852 crore. Sakar Healthcare PE 61.80, mkt cap Rs 2,230 crore. Shree Ganesh Remedies PE 58.77, mkt cap Rs 907 crore.
Quick Answer
Kilitch Drugs (India) vs Sakar Healthcare vs Shree Ganesh Remedies is a side-by-side comparison of three companies from the pharma and biotech space. On this comparison, Kilitch Drugs (India) carries a market capitalisation of about Rs 852 crore, against Rs 2,230 crore for Sakar Healthcare and Rs 907 crore for Shree Ganesh Remedies, with return on equity of 10.79%, 9.40% and 10.90% respectively. Each company’s numbers are presented here without a declared preference, since the right stock depends on an investor’s own criteria.
Kilitch Drugs (India) vs Sakar Healthcare vs Shree Ganesh Remedies starts with the core numbers most investors compare within the pharma and biotech segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.
All three names sit in the pharma and biotech bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.
Click Here – Get Free Investment Predictions
Kilitch Drugs (India), Sakar Healthcare and Shree Ganesh Remedies: Company Overview
Kilitch Drugs (India) is a listed Indian company in the pharma and biotech space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 852 crore, a return on equity of 10.79% and a book value of Rs 79.99 per share. Its quarterly revenue moved from Rs 45.70 crore in June 2025 to Rs 47.78 crore in June 2026, a change of +4.6%.
Sakar Healthcare is a listed Indian company in the pharma and biotech space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,230 crore, a return on equity of 9.40% and a book value of Rs 145.82 per share. Its quarterly revenue moved from Rs 53.13 crore in June 2025 to Rs 74.51 crore in June 2026, a change of +40.2%.
Shree Ganesh Remedies is a listed Indian company in the pharma and biotech space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 907 crore, a return on equity of 10.90% and a book value of Rs 126.95 per share. Its quarterly revenue moved from Rs 25.33 crore in June 2025 to Rs 15.30 crore in June 2026, a change of -39.6%.
Kilitch Drugs (India) vs Sakar Healthcare vs Shree Ganesh Remedies: Valuation and Profitability Snapshot
| Metric | Kilitch Drugs (India) | Sakar Healthcare | Shree Ganesh Remedies |
|---|---|---|---|
| Market Cap (approx.) | Rs 852 crore | Rs 2,230 crore | Rs 907 crore |
| PE Ratio (TTM) | 29.19 | 61.80 | 58.77 |
| PB Ratio | 3.05 | 6.87 | 5.56 |
| Return on Equity (ROE) | 10.79% | 9.40% | 10.90% |
| EPS (TTM, Rs) | 8.35 | 16.22 | 12.02 |
| Dividend Yield | 0.00% | 0.00% | 0.00% |
| Debt to Equity | 0.32 | 0.17 | 0.19 |
| Book Value per Share (Rs) | 79.99 | 145.82 | 126.95 |
Check the Univest Screener for Live Data
On valuation, Kilitch Drugs (India) trades at a PE of 29.19 and a PB of 3.05, Sakar Healthcare at a PE of 61.80 and a PB of 6.87, while Shree Ganesh Remedies trades at a PE of 58.77 and a PB of 5.56. On return on equity, the three post 10.79%, 9.40% and 10.90% respectively, and on dividend yield they stand at 0.00%, 0.00% and 0.00%. Sakar Healthcare has the highest market capitalisation of the three at Rs 2,230 crore, while Kilitch Drugs (India) has the lowest at Rs 852 crore. Sakar Healthcare has the highest PE ratio of the three at 61.80, while Kilitch Drugs (India) has the lowest at 29.19. Shree Ganesh Remedies has the highest return on equity of the three at 10.90%, while Sakar Healthcare has the lowest at 9.40%. Kilitch Drugs (India) has the highest debt to equity ratio of the three at 0.32, while Sakar Healthcare has the lowest at 0.17. Debt to equity is 0.32, 0.17 and 0.19 for the three respectively.
Kilitch Drugs (India) vs Sakar Healthcare vs Shree Ganesh Remedies: Latest Quarterly Results
| Company | Latest Quarter Revenue | Latest Quarter Net Profit | YoY Change (Revenue) | QoQ Change (Revenue) | YoY Change (Net Profit) |
|---|---|---|---|---|---|
| Kilitch Drugs (India) | Rs 47.78 crore | Rs 1.97 crore | +4.6% | -47.0% | -12.8% |
| Sakar Healthcare | Rs 74.51 crore | Rs 10.28 crore | +40.2% | +4.5% | +120.1% |
| Shree Ganesh Remedies | Rs 15.30 crore | Rs 1.12 crore | -39.6% | -55.3% | -67.5% |
Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.
Kilitch Drugs (India) vs Sakar Healthcare vs Shree Ganesh Remedies: Five-Quarter Revenue and Net Profit Trend
The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Kilitch Drugs (India) vs Sakar Healthcare vs Shree Ganesh Remedies, which helps separate a one-quarter move from a steadier pattern.
Quarterly revenue (Rs crore)
| Quarter | Kilitch Drugs (India) | Sakar Healthcare | Shree Ganesh Remedies |
|---|---|---|---|
| June 2025 | Rs 45.70 crore | Rs 53.13 crore | Rs 25.33 crore |
| September 2025 | Rs 55.58 crore | Rs 58.77 crore | Rs 31.01 crore |
| December 2025 | Rs 55.34 crore | Rs 70.85 crore | Rs 21.77 crore |
| March 2026 | Rs 90.09 crore | Rs 71.27 crore | Rs 34.22 crore |
| June 2026 | Rs 47.78 crore | Rs 74.51 crore | Rs 15.30 crore |
Quarterly net profit (Rs crore)
| Quarter | Kilitch Drugs (India) | Sakar Healthcare | Shree Ganesh Remedies |
|---|---|---|---|
| June 2025 | Rs 2.26 crore | Rs 4.67 crore | Rs 3.45 crore |
| September 2025 | Rs 8.04 crore | Rs 4.54 crore | Rs 4.96 crore |
| December 2025 | Rs 4.32 crore | Rs 10.25 crore | Rs 3.09 crore |
| March 2026 | Rs 14.88 crore | Rs 11.02 crore | Rs 6.27 crore |
| June 2026 | Rs 1.97 crore | Rs 10.28 crore | Rs 1.12 crore |
Kilitch Drugs (India) reported revenue of Rs 45.70 crore in June 2025 and Rs 47.78 crore in June 2026, a change of +4.6% across the period. Its highest quarterly revenue in this window was Rs 90.09 crore in March 2026. Net profit stood at Rs 1.97 crore in June 2026, which is a net profit margin of 4.12%.
Sakar Healthcare reported revenue of Rs 53.13 crore in June 2025 and Rs 74.51 crore in June 2026, a change of +40.2% across the period. Its highest quarterly revenue in this window was Rs 74.51 crore in June 2026. Net profit stood at Rs 10.28 crore in June 2026, which is a net profit margin of 13.80%.
Shree Ganesh Remedies reported revenue of Rs 25.33 crore in June 2025 and Rs 15.30 crore in June 2026, a change of -39.6% across the period. Its highest quarterly revenue in this window was Rs 34.22 crore in March 2026. Net profit stood at Rs 1.12 crore in June 2026, which is a net profit margin of 7.32%.
Download the Univest iOS App or Univest Android App to track Kilitch Drugs (India), Sakar Healthcare and Shree Ganesh Remedies live prices.
What Should Investors Look at Beyond These Numbers?
Beyond the metrics above, investors comparing these three pharma and biotech names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as regulatory approvals, export order flow, raw material costs and the mix between domestic and regulated-market sales. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.
It also helps to read the latest quarterly filings and investor presentations of Kilitch Drugs (India), Sakar Healthcare and Shree Ganesh Remedies directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.
Conclusion
Kilitch Drugs (India) vs Sakar Healthcare vs Shree Ganesh Remedies highlights how differently three companies in the same pharma and biotech segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information as of October 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Kilitch Drugs (India) vs Sakar Healthcare vs Shree Ganesh Remedies
What is the market cap difference between Kilitch Drugs (India), Sakar Healthcare and Shree Ganesh Remedies?
Ans. As of October 2026, Kilitch Drugs (India) has a market cap of approximately Rs 852 crore, Sakar Healthcare is at approximately Rs 2,230 crore, and Shree Ganesh Remedies is at approximately Rs 907 crore. Sakar Healthcare is the largest of the three, and its market capitalisation is about 2.6 times that of Kilitch Drugs (India), the smallest. Market capitalisation reflects the size of a company in the market rather than the quality of its business, so a larger value does not by itself signal a higher quality company. These figures move with the share price every trading day, which is why the table above should be read as a snapshot rather than a fixed ranking in the Kilitch Drugs (India) vs Sakar Healthcare vs Shree Ganesh Remedies comparison.
What are the PE and PB ratios of Kilitch Drugs (India), Sakar Healthcare and Shree Ganesh Remedies?
Ans. As of October 2026, the PE ratios stand at 29.19, 61.80 and 58.77 respectively, and the price to book ratios stand at 3.05, 6.87 and 5.56 respectively. All three companies have a positive trailing PE, so the multiples can be compared directly. The PE ratio shows how much investors pay for each rupee of trailing earnings, while the PB ratio compares the market value with the net assets on the balance sheet. Both multiples should be read against the segment norms for pharma and biotech and against each company’s own growth and earnings stability, because a high multiple can reflect expected growth or simply a small earnings base.
Which of the three has the highest ROE?
Ans. Kilitch Drugs (India), Sakar Healthcare and Shree Ganesh Remedies post ROE of 10.79%, 9.40% and 10.90% respectively as of October 2026. Shree Ganesh Remedies has the highest return on equity of the three at 10.90%, while Sakar Healthcare has the lowest at 9.40%. Return on equity measures how much profit a company generates on the capital contributed by its shareholders, so it is a useful gauge of how efficiently equity is being used. A negative ROE points to losses over the period, and a very high ROE can sometimes result from a small equity base rather than operating performance. It is therefore worth reading ROE together with debt levels and the five-quarter profit trend before drawing any conclusion from the Kilitch Drugs (India) vs Sakar Healthcare vs Shree Ganesh Remedies figures.
Which of these three stocks pays the highest dividend yield?
Ans. Kilitch Drugs (India), Sakar Healthcare and Shree Ganesh Remedies carry dividend yields of 0.00%, 0.00% and 0.00% respectively as of October 2026. Dividend yield is the annual dividend per share expressed as a percentage of the current share price, so it changes whenever the price changes. A low or zero yield is common among companies that retain profits to fund expansion, repay debt or absorb losses, and it does not by itself say anything about business quality. Investors who care about income should also check how consistently each company has paid dividends and what share of profit it distributes.
What is the debt to equity ratio for Kilitch Drugs (India), Sakar Healthcare and Shree Ganesh Remedies?
Ans. Kilitch Drugs (India) carries a debt to equity of 0.32, Sakar Healthcare of 0.17, and Shree Ganesh Remedies of 0.19. Kilitch Drugs (India) has the highest debt to equity ratio of the three at 0.32, while Sakar Healthcare has the lowest at 0.17. The debt to equity ratio compares total borrowings with shareholders’ funds, and a higher figure means the company relies more on borrowed money to run its business. What counts as a comfortable level differs by segment, since some businesses in pharma and biotech need heavy capital and carry more debt than others. Investors usually read this ratio alongside interest costs and cash generation to judge how well each company can service its borrowings in the Kilitch Drugs (India) vs Sakar Healthcare vs Shree Ganesh Remedies comparison.
What were the latest quarterly revenue and net profit of Kilitch Drugs (India), Sakar Healthcare and Shree Ganesh Remedies?
Ans. For Q1 FY27 (quarter ended June 2026), Kilitch Drugs (India) reported revenue of Rs 47.78 crore and net profit of Rs 1.97 crore, Sakar Healthcare reported revenue of Rs 74.51 crore and net profit of Rs 10.28 crore, and Shree Ganesh Remedies reported revenue of Rs 15.30 crore and net profit of Rs 1.12 crore. Compared with the quarter ended June 2025, revenue changed by +4.6% for Kilitch Drugs (India), +40.2% for Sakar Healthcare and -39.6% for Shree Ganesh Remedies. A single quarter can be affected by seasonality, one-time items and the timing of orders, so the five-quarter tables above give a clearer sense of direction than any one result. A net loss in a quarter does not always mean a troubled business, but it does call for a closer look at costs, debt and the reasons behind the swing in the Kilitch Drugs (India) vs Sakar Healthcare vs Shree Ganesh Remedies results.
Does this comparison recommend one of Kilitch Drugs (India), Sakar Healthcare and Shree Ganesh Remedies?
Ans. This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor’s own criteria and research. Instead of a verdict, the tables above lay out the figures so that readers can weigh them against their own goals, time horizon and tolerance for risk. For companies in pharma and biotech, it also helps to look at factors such as regulatory approvals, export order flow, raw material costs and the mix between domestic and regulated-market sales. Reading the latest filings and investor presentations of Kilitch Drugs (India), Sakar Healthcare and Shree Ganesh Remedies directly, and speaking to a SEBI registered adviser where needed, is a sensible step before acting on any numbers shown in Kilitch Drugs (India) vs Sakar Healthcare vs Shree Ganesh Remedies.
